US2019322707A1PendingUtilityA1

Mutated Salmonella Enterica

Assignee: US AGRICULTUREPriority: Jan 6, 2014Filed: May 31, 2019Published: Oct 24, 2019
Est. expiryJan 6, 2034(~7.4 yrs left)· nominal 20-yr term from priority
A61K 39/0275A61K 2039/543C07K 14/255A61K 2039/55A61K 2039/522A61K 2039/552A61K 2039/58Y02A50/30
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A novel, mutated Salmonella enterica serovar Typhimurium vaccine is generated and imparts protective immunity in vaccinated animals for a range of S. enterica serovars. The vaccine can be attenuated or inactivated, including bacterial ghosts or membrane fractions thereof. Immunogenic compositions are included in the invention and methods of generating an immune response.

Claims

exact text as granted — not AI-modified
1 - 91 . (canceled) 
     
     
         92 . A method of generating an immune response in an animal against a  Salmonella enterica  serovar comprising administering to said animal an immunologically effective amount of an immunogenic composition comprising a pharmaceutically acceptable carrier or diluent and a membrane fraction of a mutated  S. enterica  serovar Typhimurium comprising a null mutation in invR, micA, rybB, rfaH, omrA and omrB genes, wherein said immunologically effective amount of said immunogenic composition generates an immune response in said animal. 
     
     
         93 . The method of  claim 92 , wherein said immunogenic composition further comprises an adjuvant. 
     
     
         94 . The method of  claim 92 , wherein said mutated  S. enterica  serovar Typhimurium is selected from the group consisting of  S. enterica  serovar Typhimurium strain BBS 866 deposited under the accession number NRRL B-50989,  S. enterica  serovar Typhimurium strain BBS 1134 deposited under the accession number NRRL B-50990, and a combination thereof. 
     
     
         95 . The method of  claim 92 , wherein immune response in said animal is cross-reactive with  S. enterica  serovar Typhimurium,  S. enterica  serovar Choleraesuis,  S. enterica  serovar Heidelberg,  S. enterica  serovar Paratyphi,  S. enterica  serovar Dublin,  S. enterica  serovar Abortus-equi,  S. enterica  serovar Abortus-ovi,  S. enterica  serovar Enteritidis,  S. enterica  serovar Arizonae, and  S. enterica  serovar Gallinarum. 
     
     
         96 .- 98 . (canceled) 
     
     
         99 . The method of  claim 92 , wherein said immune response is a humoral immune response. 
     
     
         100 . The method of  claim 92 , wherein said immune response is a cellular immune response.

Join the waitlist — get patent alerts

Track US2019322707A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.